PPAR gamma Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Jee-Young | - |
dc.contributor.author | Kim, Ye-Ji | - |
dc.contributor.author | Kim, Lucia | - |
dc.contributor.author | Choi, Suk-Jin | - |
dc.contributor.author | Park, In-Suh | - |
dc.contributor.author | Kim, Joon-Mee | - |
dc.contributor.author | Chu, Young Chae | - |
dc.contributor.author | Cha, Dae-Ryong | - |
dc.date.accessioned | 2021-09-08T05:54:25Z | - |
dc.date.available | 2021-09-08T05:54:25Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-01 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/117196 | - |
dc.description.abstract | The peroxisome proliferator activated receptor (PPAR)gamma agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPAR gamma agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and p-Smad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-beta 1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-beta/Smad2 in the treated groups, PAI-1 and TGF-beta are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPAR gamma agonist might be used in the treatment of renal fibrotic disease. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | - |
dc.subject | GROWTH-FACTOR | - |
dc.subject | TROGLITAZONE | - |
dc.subject | EXPRESSION | - |
dc.subject | GLOMERULOSCLEROSIS | - |
dc.subject | ROSIGLITAZONE | - |
dc.subject | PROTEINURIA | - |
dc.subject | PROTECTS | - |
dc.subject | COLLAGEN | - |
dc.subject | DISEASE | - |
dc.title | PPAR gamma Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, Dae-Ryong | - |
dc.identifier.doi | 10.3346/jkms.2010.25.1.35 | - |
dc.identifier.scopusid | 2-s2.0-77949324227 | - |
dc.identifier.wosid | 000273367200008 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.25, no.1, pp.35 - 41 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 25 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 41 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001407436 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR | - |
dc.subject.keywordPlus | TROGLITAZONE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | GLOMERULOSCLEROSIS | - |
dc.subject.keywordPlus | ROSIGLITAZONE | - |
dc.subject.keywordPlus | PROTEINURIA | - |
dc.subject.keywordPlus | PROTECTS | - |
dc.subject.keywordPlus | COLLAGEN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | PPAR gamma | - |
dc.subject.keywordAuthor | Receptors | - |
dc.subject.keywordAuthor | Angiotensin | - |
dc.subject.keywordAuthor | Fibrosis | - |
dc.subject.keywordAuthor | Plasminogen Activator Inhibitor 1 | - |
dc.subject.keywordAuthor | Transforming Growth Factor Beta | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.